Suppr超能文献

经皮冠状动脉介入治疗后支架边缘再狭窄机制及治疗结果的血管内超声评估

Intravascular ultrasound assessment of stent edge restenosis mechanisms and treatment outcomes following percutaneous coronary intervention.

作者信息

Wu Xi, Liu Zhe, Huang Haobo, Wu Mingxing, Huang He, Wang Lei

机构信息

Department of Cardiology, Xiangtan Central Hospital (the affiliated hospital of Hunan University), Xiangtan, 411100, Hunan, People's Republic of China.

出版信息

Sci Rep. 2025 May 10;15(1):16298. doi: 10.1038/s41598-025-01381-9.

Abstract

This study aimed to elucidate the biological or mechanical causes of stent edge restenosis (SER) via intravascular ultrasound (IVUS). A retrospective assessment was conducted on 126 SER lesions that underwent IVUS prior to revascularization. The primary mechanisms of SER were categorized. (1) neointimal hyperplasia (NIH); (2) neoatherosclerosis; (3) uncovered lesion; (4) stent underexpansion; or (5) a protruding calcified nodule (CN). The predominant biological or mechanical causes of SER were NIH in 42.9% (n = 54) of lesions, neoatherosclerosis in 32.5% (n = 41), uncovered lesion in 14.3% (n = 18), stent underexpansion in 7.9% (n = 10), and protruding CN in 2.4% (n = 3). The 2-year device-oriented clinical endpoints (DoCE) incidence was 7.1% (n = 9). The group with biological causes treated via drug-coated balloons (DCB) exhibited a comparable DoCE rate (9.5%) to those with biological causes treated with drug-eluting stents (DES) and mechanical causes managed with or without restenting (6.0%, HR 2.78, 95% CI: 0.91-9.21; p = 0.161). The majority of the analyzed SERs were attributed to biological causes, including NIH, neoatherosclerosis, and uncovered lesions. The 2-year DoCE rate within patients receiving DCB for mechanically or biologically induced SER was similar to that observed in patients receiving new DES.

摘要

本研究旨在通过血管内超声(IVUS)阐明支架边缘再狭窄(SER)的生物学或机械学原因。对126例在血运重建前接受IVUS检查的SER病变进行了回顾性评估。对SER的主要机制进行了分类:(1)内膜增生(NIH);(2)新生动脉粥样硬化;(3)病变未覆盖;(4)支架扩张不足;或(5)突出的钙化结节(CN)。SER的主要生物学或机械学原因中,NIH占42.9%(n = 54)的病变,新生动脉粥样硬化占32.5%(n = 41),病变未覆盖占14.3%(n = 18),支架扩张不足占7.9%(n = 10),突出的CN占2.4%(n = 3)。2年的器械导向临床终点(DoCE)发生率为7.1%(n = 9)。经药物涂层球囊(DCB)治疗的生物学原因组的DoCE率(9.5%)与经药物洗脱支架(DES)治疗的生物学原因组以及接受或未接受再次支架植入治疗的机械学原因组相当(6.0%,HR 2.78,95% CI:0.91 - 9.21;p = 0.161)。大多数分析的SER归因于生物学原因,包括NIH、新生动脉粥样硬化和病变未覆盖。接受DCB治疗机械性或生物学性诱导的SER患者的2年DoCE率与接受新DES治疗的患者相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12065881/ab24e56a12a0/41598_2025_1381_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验